期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Amifostine在恶性肿瘤放疗中的应用 被引量：5

Advanced research of Amifostine in the radiotherapy to malignant tumors
下载PDF
导出
摘要 放疗是治疗恶性肿瘤的主要治疗方法之一,但往往不可避免地出现骨髓抑制等不良反应。细胞保护剂阿米福汀可以对骨髓、肝、肾等起保护作用而不影响抗肿瘤疗效。皮下注射或直肠内给药可能更适合某些病人。其细胞保护作用有一定剂量依赖性和局限性。尚不能影响肿瘤患者的生存率。 Radiotherapy is one of vital treatments to malignant tumors, but always inevitably comes up with side effects. The cell protector amifostine can protect marrow, liver and kidney without reducing anti - tumor efficiency. Subcutaneous or intrarectal administration is more suitable to some patients. The protection effect has dose dependency and limitation, can not still improve the survival rate.
作者 夏红强 金冶宁
机构地区 上海交通大学医学院附属瑞金医院肿瘤放化疗科
出处 《现代肿瘤医学》 CAS 2009年第4期774-776,共3页 Journal of Modern Oncology
关键词 阿米福汀 细胞保护剂 肿瘤 放疗 amifostine cell protector tumor radiotherapy
分类号 R730.55 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Koukourakis MI. Amifostine in clinical oncology : current use and future applications [ J ]. Anticancer Drugs, 2002, 13 ( 3 ) : 181 - 209.
  • 2Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients [ J ]. Radiother Oncol,2004,70 ( 3 ) :261 - 264.
  • 3Kouloulias VE, Kouvaris JR, Kokakis JD, et al. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy : a retrospective analysis [ J ]. Int J Radiat Oncol Biol Phys, 2004,59 (4) : 1148 - 1156.
  • 4Jellema AP, Slotman B J, Muller M J, et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly : A prospective randomized study in squamous cell head and neck cancer[ J ]. Cancer, 2006,107 (3): 544 - 553.
  • 5Ozsahin M, Betz M, Matzinger O, et al. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant - boost radiation therapy [ J ]. Arch Otolaryngol Head Neck Surg, 2006, 132 (2) :141 - 145.
  • 6Bardet E, Martin L, Calais G,, et al. Preliminary data of the GORTEC 2000 - 02 phase Ⅲ trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy [ J ]. Semin Oncol, 2002, 29(6 Suppl 19) :57 -60.
  • 7Singh AK, Menard C, Guion P, et al. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer:a pilot study [ J ]. Int J Radiat Oncol Biol Phys, 2006,65(4) :1008 - 1013.
  • 8Kouloulias VE, Kouvaris JR, Pissakas G, et al. Phase Ⅱ multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity : topical intrarectal versus subcutaneous application [ J ]. Int J Radiat Oncol Biol Phys,2005,62(2) :486 -493.
  • 9Veerasarn V, Phromratanapongse P, Suntompong N, et al. Effect of Amifostine to prevent radiotherapy - induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function[ J ]. J Med Assoc Thai ,2006,89 (12) :2056 - 2067.
  • 10Munter MW, Hoffner S, Hof H, et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity - modulated radiotherapy and conventional radiation therapy with and without Amifostine[ J]. Int J Radiat Oncol Biol Phys,2007, 67(3) :651 -659.

同被引文献36

引证文献5

二级引证文献10

现代肿瘤医学
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部